Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy

Quality of Life Research

Volumn 25, Issue 10, 2016, Pages 2535-2541

  Raman, Srinivas ^a   Ding, Keyue ^b   Chow, Edward ^a,o   Meyer, Ralph M ^c   Nabid, Abdenour ^d   Chabot, Pierre ^e   Coulombe, Genevieve ^f   Ahmed, Shahida ^g   Kuk, Joda ^h   Dar, A Rashid ⁱ   Mahmud, Aamer ^j   Fairchild, Alysa ^k   Wilson, Carolyn F ^b   Wu, Jackson S Y ^l   Dennis, Kristopher ^m   DeAngelis, Carlo ^a   Wong, Rebecca K S ^a   Zhu, Liting ^b   Brundage, Michael ⁿ  

^a UNIVERSITY OF TORONTO   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^e MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

^g CANCERCARE MANITOBA   (Canada)

^h Grand River Regional Cancer Centre   (Canada)

ⁱ LONDON REGIONAL CANCER PROGRAM   (Canada)

^j KINGSTON GENERAL HOSPITAL   (Canada)

^k CROSS CANCER INSTITUTE   (Canada)

^l UNIVERSITY OF CALGARY   (Canada)

^m OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

ⁿ QUEEN S UNIVERSITY   (Canada)

^o DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

more..

Author keywords

Bone metastases; EORTC QLQ BM22 module; EORTC QLQ C15 PAL module; Minimal clinically important differences; Radiation

Indexed keywords

ADULT; AGED; APPETITE; ARTICLE; BONE METASTASIS; CANCER FATIGUE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DETERIORATION; DYSPNEA; EMOTIONALITY; EORTC QLQ BM22 MODULE; EORTC QLQ C15 PAL MODULE; FEMALE; FOLLOW UP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME; BONE NEOPLASMS; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SECONDARY; SICKNESS IMPACT PROFILE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; NEOPLASM METASTASIS; PALLIATIVE CARE; PROSPECTIVE STUDIES; SICKNESS IMPACT PROFILE; SURVEYS AND QUESTIONNAIRES;

EID: 84965017997     PISSN: 09629343     EISSN: 15732649     Source Type: Journal    
DOI: 10.1007/s11136-016-1308-4     Document Type: Article

References (20)

1. Lutz, S., Berk, L., Chang, E., Chow, E., Hahn, C., Hoskin, P., et al. (2011). Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. International Journal of Radiation Oncology Biology Physics, 79(4), 965–976.
2. Chow, E., Hird, A., Velikova, G., Johnson, C., Dewolf, L., Bezjak, A., et al. (2009). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. European Journal of Cancer, 45(7), 1146–1152.
3. Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., et al. (2006). The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care. European Journal of Cancer, 42(1), 55–64.
4. Zeng, L., Chow, E., Bedard, G., Zhang, L., Fairchild, A., Vassiliou, V., et al. (2012). Quality of life after palliative radiation therapy for patients with painful bone metastases: Results of an international study validating the EORTC QLQ-BM22. International Journal of Radiation Oncology Biology Physics, 84(3), e337–e342.
5. Chow, E., Nguyen, J., Zhang, L., Tseng, L. M., Hou, M. F., Fairchild, A., et al. (2012). International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer, 118(5), 1457–1465.
6. Caissie, A., Zeng, L., Nguyen, J., Zhang, L., Jon, F., Dennis, K., et al. (2012). Assessment of health-related quality of life with the European organization for research and treatment of cancer QLQ-C15-PAL after palliative radiotherapy of bone metastases. Clinical Oncology, 24(2), 125–133.
7. Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56(5), 395–407.
8. Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61(2), 102–109.
9. Chow, E., Meyer, R. M., Ding, K., Nabid, A., Chabot, P., Wong, P., et al. (2015). Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: A double-blind, randomised placebo-controlled, phase 3 trial. The lancet Oncology, 16(15), 1463–1472.
10. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.
11. Maringwa, J., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., et al. (2011). Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Annals of Oncology, 22, 2107–2112.
12. Maringwa, J. T., Quinten, C., King, M., Ringash, J., Osoba, D., Coens, C., et al. (2011). Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Supportive Care in Cancer, 19(11), 1753–1760.
13. Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139–144.
14. King, M. T. (1996). The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of Life Research, 5(6), 555–567.
15. Bedard, G., Zeng, L., Zhang, L., Lauzon, N., Holden, L., Tsao, M., et al. (2016). Minimal important differences in the EORTC QLQ‐C15‐PAL to determine meaningful change in palliative advanced cancer patients. Asia‐Pacific Journal of Clinical Oncology, 12(1), e38–e46.
16. Zeng, L., Chow, E., Zhang, L., Tseng, L. M., Hou, M. F., Fairchild, A., et al. (2012). An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. Supportive Care in Cancer, 20(12), 3307–3313.
17. Ringash, J., O’Sullivan, B., Bezjak, A., & Redelmeier, D. A. (2007). Interpreting clinically significant changes in patient-reported outcomes. Cancer, 110(1), 196–202.
18. Cella, D., Hahn, E. A., & Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Quality of Life Research, 11(3), 207–221.
19. Yost, K. J., Cella, D., Chawla, A., Holmgren, E., Eton, D. T., Ayanian, J. Z., & West, D. W. (2005). Minimally important differences were estimated for the functional assessment of cancer therapy-colorectal (FACT-C) instrument using a combination of distribution-and anchor-based approaches. Journal of Clinical Epidemiology, 58(12), 1241–1251.
20. Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592.